Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rafia Bhore

Showing results (31-40 of 56) with videos related to

Pageof 6
Sort By:
Future Oncology (London, England)|April 2, 2020
Quality of life with second or third line <i>nab</i>-paclitaxel-based regimens in advanced non-small-cell lung cancerSantiago Ponce Aix, Denis Talbot, Ramaswamy Govindan, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|December 20, 2015
Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysisJia-Horng Kao, Donald M Jensen, Michael P Manns, et al.
Japanese Journal of Ophthalmology|December 26, 2025
Intravitreal aflibercept 8 mg in patients from Japan with diabetic macular edema: 48-week subgroup analysis of the PHOTON trialKiyoshi Suzuma, Toshinori Murata, Masahiko Shimura, et al.
The New England Journal of Medicine|October 4, 2023
Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid TaperRobert F Spiera, Sebastian Unizony, Kenneth J Warrington, et al.
Japanese Journal of Ophthalmology|December 26, 2025
Intravitreal aflibercept 8 mg in patients from Japan with neovascular age-related macular degeneration: 48-week subgroup analysis of the PULSAR trialHideki Koizumi, Shigeru Honda, Tsutomu Yasukawa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2017
Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III TrialsDirk Schadendorf, Jedd D Wolchok, F Stephen Hodi, et al.
Open Forum Infectious Diseases|May 25, 2023
Effectiveness of Casirivimab and Imdevimab Antibody Combination in Immunocompromised Hospitalized Patients With Coronavirus Disease 2019: A Post Hoc Analysis in a Phase 1/2/3 Double-Blind TrialSelin Somersan-Karakaya, Eleftherios Mylonakis, Jenni Mou, et al.
Clinical Lung Cancer|October 24, 2020
Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non-Small-cell Lung Cancer (ABOUND.sqm): A Phase III Randomized Clinical TrialDavid R Spigel, Robert M Jotte, Santiago Ponce Aix, et al.
Cancer|November 2, 2018
ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC-486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC)Daniel Morgensztern, Manuel Cobo, Santiago Ponce Aix, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2017
Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced MelanomaMario Sznol, Pier Francesco Ferrucci, David Hogg, et al.
Pageof 6

Showing results (31-40 of 56) with videos related to

Sort By:
Pageof 6
Future Oncology (London, England)|April 2, 2020
Quality of life with second or third line <i>nab</i>-paclitaxel-based regimens in advanced non-small-cell lung cancerSantiago Ponce Aix, Denis Talbot, Ramaswamy Govindan, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|December 20, 2015
Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysisJia-Horng Kao, Donald M Jensen, Michael P Manns, et al.
Japanese Journal of Ophthalmology|December 26, 2025
Intravitreal aflibercept 8 mg in patients from Japan with diabetic macular edema: 48-week subgroup analysis of the PHOTON trialKiyoshi Suzuma, Toshinori Murata, Masahiko Shimura, et al.
The New England Journal of Medicine|October 4, 2023
Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid TaperRobert F Spiera, Sebastian Unizony, Kenneth J Warrington, et al.
Japanese Journal of Ophthalmology|December 26, 2025
Intravitreal aflibercept 8 mg in patients from Japan with neovascular age-related macular degeneration: 48-week subgroup analysis of the PULSAR trialHideki Koizumi, Shigeru Honda, Tsutomu Yasukawa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2017
Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III TrialsDirk Schadendorf, Jedd D Wolchok, F Stephen Hodi, et al.
Open Forum Infectious Diseases|May 25, 2023
Effectiveness of Casirivimab and Imdevimab Antibody Combination in Immunocompromised Hospitalized Patients With Coronavirus Disease 2019: A Post Hoc Analysis in a Phase 1/2/3 Double-Blind TrialSelin Somersan-Karakaya, Eleftherios Mylonakis, Jenni Mou, et al.
Clinical Lung Cancer|October 24, 2020
Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non-Small-cell Lung Cancer (ABOUND.sqm): A Phase III Randomized Clinical TrialDavid R Spigel, Robert M Jotte, Santiago Ponce Aix, et al.
Cancer|November 2, 2018
ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC-486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC)Daniel Morgensztern, Manuel Cobo, Santiago Ponce Aix, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2017
Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced MelanomaMario Sznol, Pier Francesco Ferrucci, David Hogg, et al.
Pageof 6